微小残留病变

探讨定量检测CML微小残留病变（minimalresidualdisease，MRD）的临床意义。

And evaluate its clinical value in the minimal residual disease ( MRD ) .

Bcl-2基因重排在恶性淋巴瘤微小残留病变检测中的应用

Bcl 2 / JH gene re arrangement determined by PCR as a means to detect minimal residual disease in malignant lymphomas

竞争性定量RT-PCR技术在t（8；21）AML微小残留病变检测中的应用

The application of competitive RT PCR to detect minimal residual disease in patients with 8 ; 21 translocation

Ph~+/bcr-abl~+急性淋巴细胞白血病微小残留病变的细胞遗传学分析、巢式RT-PCR及流式细胞术检测

Detection of Minimal Residual Disease in Ph ~ + / bcr-abl ~ + Acute Lymphoblast Leukemia by Cytogenetic Analysis , Nested-PCR and Flow Cytometry

STR-PCR联合RT-PCR技术在慢性髓细胞白血病患者异基因造血干细胞移植后微小残留病变检测中的应用

Detection of Minimal Residual Disease of Chronic Myeloid Leukemia Patients after Allogeneic Stem Cell Transplantation by Combination of STR-PCR with RT-PCR

结论bcr/abl融合基因检测有助于CML和ALL的临床诊断、治疗选择、微小残留病变（MRD）监测以及预后判断；

Conclusions The detection of bcr / abl fusion gene is significant in clinic diagnosis , choice of treatment , monitoring minimal residual disease ( MRD ) and estimating prognosis in leukemia .

目的：应用筑巢式RTPCR（RTnestPCR）法检测慢性髓细胞性白血病（CML）患者非亲缘异基因骨髓移植（URD）后微小残留病变（MRD），并探讨它与复发的相关性。

Objective : To detect minimal residual disease ( MRD ) after unrelated donor allogeneic bone marrow transplantation ( URD-BMT ) in chronic myeloid leukemia ( CML ) with nested reverse transcriptase polymerase chain reaction ( RT-nest-PCR ) in order to explore its relationship with relapse .

多发性骨髓瘤完全缓解后微小残留病变的检测进展及意义

The progression and significance of minimal residual disease detection after complete remission patients with multiple myeloma

非霍奇金淋巴瘤微小残留病变检测的方法及临床意义

A Meta-analysis of the Methos and the Signifcances of Detecting Non-hodgkin 's Lymphoma 's Minimal Residual Diseases

多参数流式细胞术对急性髓系白血病微小残留病变与疾病复发的监测

Prognosticating Relapse Risk Based on Multiparameter Flow Cytometric Assessment of Minimal Residual Disease in Patients with Acute Myeloid Leukemia

主动免疫治疗是消除微小残留病变及延长白血病患者化疗后无病生存期的可行而有效的途径，其基本原理是用肿瘤抗原激发机体产生特异性抗肿瘤免疫。

Active immunotherapy is a feasible and effective method in eliminating minimal resid - ual disease and prolonging disease-free survival time of leukemia patients after chemotherapy . The basic principal of active immunotherapy is to enhance host specific anti-tumor immune function after it has been stimulated with tumor antigen .